Geddes, D. M., Rudolf, M., and Saunders, K. B. (1976) . Thorax, 31, [548] [549] [550] [551] Effect of nitrazepam and flurazepam on the ventilatory response to carbon dioxide. Ventilatory response to CO2 was measured before and after two different benzodiazepine hypnotics in both chronic bronchitics and patients without chest disease. Flurazepam, but not nitrazepam, produced a significant decrease in CO2 sensitivity, although there was no significant change in FEV, or mixed venous Pco2. This is the first unequivocal evidence of central depression of respiration by a benzodiazepine and may be the mechanism by which benzodiazepines cause deterioration in patients with respiratory failure.
It is generally accepted that any form of sedative may cause deterioration in a patient with respiratory failure. This has been attributed to depression of central respiratory drive, and impaired ventilatory response to carbon dioxide has been well demonstrated with both morphine and barbiturates (Weil et al., 1975; Gasser, Kaufman, and Bellville, 1975) . Benzodiazepines have been reported to cause deterioration in patients with chronic respiratory failure during an acute exacerbation (Clark, Collins, and Tong, 1971) , but the effect of these drugs on such patients when they are in a stable state is less well established and the mechanism of the respiratory depression is unknown. In one of the patients reported by Clark et al. (1971) , administration of nitrazepam was followed by a severe worsening of respiratory failure although that patient had taken the same drug on previous occasions without ill-effect. It was suggested that acute pulmonary infection might increase the susceptibility to respiratory depression. There is, however, no good evidence that benzodiazepines are respiratory depressants in normal subjects or in patients with stable chronic respiratory disease.
We have therefore conducted a double-blind cross-over trial using nitrazepam, flurazepam (Borland and Nicholson, 1975 Table I . There were no significant differences between the control values obtained before each of the three tablets was taken. Neither placebo nor nitrazepam produced any significant change in ventilatory response. However, after flurazepam CO2 sensitivity was significantly decreased (P<0-02), and indeed no ventilatory response could be detected in two patients after taking this drug. No significant differences between the intercepts at zero ventilation were found.
The bronchitic group had a lower mean ventilatory response than the non-respiratory group, but there was no difference between the two groups in the effect of the drugs on CO2 responsiveness and they were therefore combined for statistical analysis. Non-respiratory 2-78 2-81 2-83 2-86 2-83 2-82 All subjects 2-13 2-12 2-13 2-15 2-16 2-17 Bronchitic 6-96 6-45 6-03 6-19 6-84 6-80 Pvco0
Non-respiratory 6-43 6-43 6-27 6-35 6-03 6-18
All subjects 6-69 6-44 6-15 6-27 6-43 6-55 Rao et al. (1973) found slight depression of ventilation after diazepam but this was comparable to that occurring during normal sleep. Clark et al. (1971) reported three patients with acute on chronic respiratory failure in whom nitrazepam had apparently caused dangerous deterioration. This effect was confirmed by Pines (1972) . All these patients deteriorated within hours of the drug being taken. In 1973 Model reported two further patients whose respiratory failure deteriorated following nitrazepam but only after the drug had been taken for nine days in one case and for 21 days in the other. It is not clear from this last report whether the drug was the sole factor responsible for the deterioration or whether an acute infection also played some part. Gaddie et al. (1972) performed a double-blind cross-over trial to study the effect of nitrazepam, 10 mg, on patients with chronic respiratory failure in a stable state. There was no significant change in arterial tensions of oxygen or carbon dioxide but the FEV1 fell significantly at two hours after ingestion of the drug. This raised the possibility that the respiratory depression previously reported might be due to an effect on skeletal muscle rather than a direct suppression of the central drive to ventilation. Similar results were obtained by Model and Berry (1974) , who showed that regular oral chlordiazepoxide caused a significant fall in FEV1, associated with a rise in PNco2, in patients with acute on chronic bronchitis.
The simplest way to assess the central drive to respiration is by measuring the ventilatory response to CO2. With this method ventilatory depression has been shown with opiates (Weil et al., 1975) and barbiturates (Gasser et al., 1975) . There have been some previous studies of the effect of benzodiazepines on the ventilatory response, although none using nitrazepam or flurazepam. Sadove, Balagot, and McGrath (1965) demonstrated respiratory depression with pethidine which was not worsened by the simultaneous administration of intravenous chlordiazepoxide or diazepam. This was confirmed by Steen and his co-workers (Steen et al., 1966; Steen et al., 1967) , who measured also the ventilatory response to CO2 after the administration of chlordiazepoxide and diazepam, both alone and with pethidine, in normal volunteers. No depression of CO2 sensitivity could be demonstrated with these benzodiazepines.
Using the rebreathing method of Read (1967) to assess ventilatory response to C02, Cohen, Finn, and Steen (1969) (1971) both in normal subjects and in patients with chronic bronchitis after intravenous diazepam. The CO2 sensitivity was reduced in some patients but unchanged and even increased in others. There was no significant change for either group overall. Gasser et al. (1975) showed marked reduction in ventilatory response to CO2 after pentobarbitone and pentazocine but no significant change after lorazepam.
The significant depression of CO2 sensitivity by flurazepam shown in our study is, to our knowledge, the first unequivocal evidence of central depression of respiration by a benzodiazepine. The lack of any change in FEV1 argues against the muscle relaxant properties of the drug being significant and implies true depression of central drive. We were unable to demonstrate any significant change after nitrazepam, which raises the possibility of different behaviour among the different drugs of this group. The doses given are approximately equal in hypnotic effect. The failure of both this study with nitrazepam and the previous studies quoted above to demonstrate respiratory depression implies that such an effect cannot be very great. It may then be important only in patients when an acute exacerbation of respiratory failure causes a deterioration in respiratory function such that any small change in central drive or muscular power becomes critical. This is supported by our observations that in spite of a change in CO2 sensitivity there was no significant change in Pvco2.
Our results refer to the effects of a single dose of benzodiazepine, not to long-term administration. We believe that the administration of sedatives or hypnotics to patients with acute respiratory failure, or an acute excerbation of chronic respiratory disease, is always contraindicated. The position for patients with chronic stable respiratory failure and CO2 retention is less certain, but we feel that the indication for sedatives, if prescribed, should be compelling, and the patient should be under close observation.
There is no good evidence that chronic bronchitics with a normal arterial carbon dioxide tension will come to harm after a single dose of a benzodiazepine. However, should such a drug be prescribed it would be reasonable to prefer 
